XXXX

Speratum is a biopharmaceutical company focused on microRNA-directed oncology therapies. The Company was founded in 2014 by Christian Marín-Müller, Ph.D. and is dedicated to the development of a patented treatment for pancreatic cancer based on the combination of tumor suppressive microRNA molecules and nanoparticle-based drug delivery technologies. The Company is currently entering the final stage of preclinical trials for the pancreatic cancer therapy, while simultaneously expanding the patent’s coverage to incorporate other types of cancer and non-cancer indications and illnesses and expanding its intellectual property (IP) portfolio with complementary technologies in the fields of nanotechnology, medical devices and veterinary medicine.